Phrozen Presents ARCO: Fast, Full-Color FDM 3D Printing for Creative Minds
TAIPEI, Nov. 10, 2025 /PRNewswire/ -- Phrozen, renowned for its leadership in resin 3D printing, expands its ecosystem with a refreshed look at ARCO, the company's first FDM 3D printer. Building on its reputation for high-precision printing, Phrozen...
Brii Biosciences Presents Late-Breaking Data from Ongoing Phase 2 ENSURE Study at AASLD 2025, Reinforcing BRII-179's Potential as a Curative Treatment for Chronic Hepatitis B
Cohort 4 follow-up confirms durable hepatitis B surface antigen (HBsAg) loss at 24 weeks post end of treatment (EOT) in BRII-179 anti-HBs responders treated with elebsiran plus pegylated interferon alfa (PEG-IFNα) Data suggest the potential to...
Rona Therapeutics Presents Phase 1 Data for RN0361, a Long-Acting APOC3-Targeting siRNA, at the American Heart Association 2025 Scientific Sessions
NEW ORLEANS, Nov. 10, 2025 /PRNewswire/ -- Rona Therapeutics, a global leader in developing next-generation RNAi therapeutics, presented highlights of Phase 1 clinical data for RN0361, a long-acting Apolipoprotein C3 (ApoC3) siRNA. RN0361 achieved...
HanchorBio Presents Two Late-Breaking Abstracts at the Society for Immunotherapy of Cancer 2025 Demonstrating Best-in-Class Potential of HCB101 in Advanced Cancers
Late-breaking poster presentations show HCB101's favorable safety, strong receptor occupancy, and promising monotherapy and combination activity in tumors historically unresponsive to immunotherapy TAIPEI, SHANGHAI, and SAN FRANCISCO, Nov. 7, 2025...
Alebund Presents Phase 3 Trial Results of AP301 at the American Society of Nephrology (ASN) 2025 Congress
Clinically and statistically significant superiority of AP301 maintenance dose versus ineffective low dose in reducing serum phosphate levels was established and AP301's efficacy is sustained throughout the 52 weeks of treatment. The non-inferiority...
AEWIN Presents Innovative Two-Phase Direct Liquid Cooling (2P DLC) Solution at SC25
TAIPEI, Nov. 5, 2025 /PRNewswire/ -- AEWIN Technologies Co., Ltd (doing business as AEWIN), a leading provider of advanced network appliances and edge computing solutions, is excited to present innovative Two-Phase Direct Liquid Cooling (2P DLC)...
HanchorBio Presents Preclinical Data on HCB301 at SITC 2025
HCB301 is a first-in-class tri-specific immunotherapy targeting SIRPα-CD47, PD-1/PD - L1, and TGFβ; it shows potent macrophage activation, T-cell restoration, and tumor microenvironment remodeling in preclinical solid tumor models. TAIPEI, SHANGHAI,...
Ascletis Presents Full Analysis of Phase Ib Study of ASC30 Oral Tablet, Phase Ib Study of ASC30 Injection, and Preclinical Study of Combination of ASC31 and ASC47 at ObesityWeek® 2025
-Positive data from Phase Ib study of ASC30 oral tablet demonstrated up to 6.5% placebo-adjusted mean body weight reduction; safe and well tolerated with only mild-to-moderate gastrointestinal (GI) adverse events (AEs) across all multiple ascending...
American Express Presents Elevated "AMEX GOURMET CLUB" with Refined Dining Offers at Over 300 Restaurants and Bars Across Hong Kong
HONG KONG, Oct. 28, 2025 /PRNewswire/ -- American Express Hong Kong today announced the refresh of "AMEX GOURMET CLUB", its signature dining program designed to bring Cardmembers an expanded suite of dining privileges and elevated culinary...
Antengene Presents Latest Preclinical Data of ATG-201 (CD19 x CD3 TCE) at ACR 2025
SHANGHAI and HONG KONG, Oct. 27, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercialising first-in-class...